Basic Information (Switzerland) Elecon Asia SA (hereinafter referred to as “Elecon”) is a powerful intelligent three-d...
Digital Copyright Ten Major Typical Cases 1.Short Video Copyright Case: Whether a Short Video is Original Has Nothing to...
December 7, 2023 - News of a patent infringement ruling against Apple Watches a few weeks ago caused a flurry of investo...
, the UK, and with the UPC. In a ruling of September 2024, the Munich Regional court found that Amazon infringed one of Nokia’s patents. JUVE Patent does not yet know if the parties will appeal today’s
Dec 16 - IBM (IBM.N) has agreed to settle a patent lawsuit against Zynga after it won a $45 million jury verdict against the mobile game maker earlier this year, according to a filing in Delaware
Author：Peiyu Liu, specialized in Intellectual Property field, especially in Patent, with Qualification of Chinese Attorney and Patent Attorney. SJD Candidate in Global Intellectual Property, MSc in
In the pan-European dispute over Soliris, Alexion has now suffered another defeat. The UK High Court found that an important patent relating to the active ingredient eculizumab would have to be
sales in other countries, and there are no lawsuits against Sunwoda elsewhere. In Germany, Sunwoda filed nullity actions against EP 139 and EP 141. The Federal Patent Court’s preliminary opinion deemed
A long-running dispute between Fresenius Medical Care and Nipro over dialysis technology has concluded in Germany. The Federal Court of Justice declared the patent-in-suit invalid, thereby removing
at the Mannheim local division concerns EP 2 028 981, the patent-in-suit at the Paris local division is EP 3 155 936. Both relate to a juice extractor. In March, the Mannheim division found that NUC
EPO, and an infringement suit was dismissed by Munich Regional Court. Today, the Mannheim local division also dismissed the infringement suit relating to the second patent. Dish accuses Aylo of
The global patent dispute between Nokia and Amazon has ended. Today, the Finnish tech company announced it had signed an agreement with the US company covering the use of Nokia's video technologies
argued there was a risk of imminent infringement of its patent EP 1 830 843 B1, which protects the use of nintedanib or nintedanib esylate, from 12 December 2024. The pharma company also owns the related
CHINA intellectual PROPERTY LAWYERS NETWORK
+86-13910160652
ciplawyers@163.com
